Salt Lake City, Utah — December 15, 2025 — Leads & Copy — Novarad Corporation announced that the United States Court of Appeals for the Federal Circuit affirmed the decision of the Patent Trial and Appeal Board (PTAB), upholding Novarad’s U.S. Patent No. 10,945,807, terminating the appeal on the merits following oral argument.
The decision stems from litigation regarding challenges by Medivis, Inc., which sought to invalidate two of Novarad’s patents covering augmented reality navigation technologies. Medivis did not prevail at the Patent Trial and Appeal Board on all challenged claims of Novarad’s U.S. Patent No. 11,004,271; the Board’s decision is also on appeal at the Federal Circuit.
Novarad CFO Michael Chandler stated that intellectual property protection is essential to sustaining innovation in augmented reality surgical navigation. Novarad alleges that Medivis is infringing on multiple additional patents and believes the litigation may expand to include major hospital systems, including the University of Pittsburgh and MD Anderson.
Headquartered in Utah, Novarad was the first company to receive FDA clearance for an augmented reality medical system for surgical planning. VisAR, Novarad’s augmented reality surgical navigation platform, enables surgeons to visualize complex anatomy and guide instruments. Novarad holds approximately 30 U.S. and international patents related to augmented reality navigation. Dr. Wendell A. Gibby, CEO of Novarad, said this technology elicits a “wow” response from doctors.
See it at www.novarad.net/visar.
Meta and Google have also invested in augmented reality platforms.
Ian Scott
Marketing & Communications, Novarad
marketing@novarad.net
(385) 265-1617
Source: Novarad Corporation
